about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Bio­mark­er 'roadmap­s' and the fu­ture of can­cer R&D; Cur­tain rais­es on #AS­CO22; Pfiz­er, No­var­tis tack­le drug ac­cess; ...

4 years ago
Weekly

Covid-19 roundup: CDC study shows good pro­tec­tion from mR­NA boost­er plus J&J's sin­gle-dose vac­cine; White House ...

4 years ago
Coronavirus

Keep­ing pres­sure on Am­gen, Mi­rati draws mixed re­views on lat­est cut of KRAS da­ta

4 years ago
R&D

Se­quoia Chi­na leads $37M in­fu­sion in­to ra­dio­phar­ma­ceu­ti­cals play­er set­ting up shop in Chi­na and Bel­gium

4 years ago
Financing
Startups

In search of elu­sive NASH break­through, Pfiz­er spot­lights com­bo ap­proach

4 years ago
R&D

For­mer Ed­i­tas CEO Ka­trine Bosley goes the VC route, join­ing ear­ly-stage in­vestor

4 years ago
People

LA biotech founder ar­rest­ed, charged in mur­der-for-hire scheme be­hind 2018 death

4 years ago
People

Chica­go-area biotech sends 2nd drug to In­di­a's reg­u­la­tors; Pen­ny stock play­er spins out PhI­II can­cer can­di­date in­to ...

4 years ago
News Briefing

Tak­ing an­oth­er shot at mR­NA glo­ry, Cure­Vac inks on­col­o­gy pact while keep­ing up with Covid work

4 years ago
Deals

Life sci­ences de­vel­op­er Bio­Med Re­al­ty buys San Fran­cis­co ho­tel for $75M — re­port

4 years ago
Deals

'Hands may be tied': FDA slaps Ver­ri­ca with 3rd CRL due to prob­lems with con­tract man­u­fac­tur­er

4 years ago
FDA+

Geno­cea reach­es end of road, delist­ing from Nas­daq and let­ting go of re­main­ing staff

4 years ago
People

Plan­ning ahead for crowd­ed ul­cer­a­tive col­i­tis mar­ket, Pfiz­er spells out PhI­II da­ta on $6.7B Are­na drug

4 years ago
R&D

Man­u­fac­tur­ing con­cerns spur clin­i­cal hold on small biotech's Alzheimer's tri­al — shares plunge

4 years ago
FDA+

Blam­ing Covid dis­rup­tion, sup­ply short­ages, mi­cro­cap biotech hits the brakes on cell ther­a­py tri­al

4 years ago
R&D
Cell/Gene Tx

Idor­sia claims PhI­II win for hy­per­ten­sion drug at cen­ter of $230M J&J deal

4 years ago
R&D

At the cusp of NDA fil­ing for lead an­tibi­ot­ic, As­traZeneca spin­out goes pri­vate at a frac­tion of IPO price

4 years ago
Deals

As GSK-part­nered Covid an­ti­body racks up glob­al sales, Vir ax­es WuXi deal and grabs back Chi­na rights

4 years ago
Deals
China

Al­con takes a crack at multi­bil­lion-dol­lar dry eye mar­ket, picks up 2 drugs from Langer spin­out

4 years ago
Deals

Amid mon­key­pox fears, biotechs spring to ac­tion; Mod­er­na’s CFO trou­ble; Cuts, cuts every­where; Craft­ing the right ...

4 years ago
Weekly

Tout­ing 100% OS rate in piv­otal rare dis­ease tri­al, Rock­et Phar­ma ready to head to FDA

4 years ago
R&D
Cell/Gene Tx

Re­silience inks man­u­fac­tur­ing pact with ARCH-backed cell ther­a­py start­up as it preps for the long haul

4 years ago
Deals
Manufacturing

As Big Phar­ma cir­cles RSV wag­ons, biotech re­ports mid-stage flop for its an­tivi­ral

4 years ago
R&D

Un­der-the-radar Chi­nese biotech scores $47M up­front in se­cre­tive Mer­ck deal around can­cer drug

4 years ago
Deals
China
First page Previous page 30313233343536 Next page Last page
A service from the Financial Times